Gastroesophageal Junction Cancer

• CLINICAL_TRIALS trial_result · 2022-01-11
  Clinical Trial Update: Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma [Phase 2]

  Phase 2 trial evaluating camrelizumab combined with SOX as adjuvant treatment for advanced gastric adenocarcinoma or gastroesophageal juncti…

• CLINICAL_TRIALS trial_result · 2021-11-04
  Clinical Trial Update: Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) [Phase 3]

  Phase 3 trial update for avelumab in first-line maintenance for unresectable, locally advanced or metastatic gastric/GEJ adenocarcinoma (JAV…

• CLINICAL_TRIALS trial_result · 2021-09-13
  Clinical Trial Update: Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers [Phase 3]

  A Phase 3 trial evaluating ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in advanced HER-…

• CLINICAL_TRIALS trial_result · 2021-08-24
  Clinical Trial Update: Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma. [Phase 2]

  Phase 2 trial evaluating porcine fibrin sealant to prevent cervical anastomotic leakage after esophageal or gastroesophageal junction cancer…

• CLINICAL_TRIALS trial_result · 2021-06-22
  Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer [Phase 3]

  A Phase 3 trial evaluating nivolumab versus placebo in patients with resected esophageal or gastroesophageal junction cancer has completed a…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2021-05-10
  Clinical Trial Update: A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer [Phase 3]

  Phase 3 study evaluating BBI608 plus weekly paclitaxel for gastric and gastroesophageal junction cancer has completed, with results posted.

• CLINICAL_TRIALS trial_result · 2020-11-17
  Clinical Trial Update: Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]

  Phase 2 trial evaluating conversion therapy with Camrelizumab plus chemoradiotherapy in patients with initially unresectable gastric or GEJ …

• CLINICAL_TRIALS trial_result · 2020-10-26
  Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers [Phase 2]

  Phase 2 clinical trial evaluating toripalimab for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma after failure …

• CLINICAL_TRIALS trial_result · 2020-09-18
  Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

  Phase 2 trial evaluating andecaliximab with nivolumab vs nivolumab alone in unresectable or recurrent gastric or gastroesophageal junction a…

• CLINICAL_TRIALS trial_result · 2020-08-11
  Clinical Trial Update: FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer [Phase 2, Phase 3]

  A Phase 2/3 trial comparing FLOT with and without HER2-targeted therapy (Herceptin/Pertuzumab) as perioperative treatment for HER-2 expressi…

• CLINICAL_TRIALS trial_result · 2020-05-11
  Clinical Trial Update: A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma [Phase 1, Phase 2]

  A Phase 1b/2 trial evaluating MEDI4736 (durvalumab) with tremelimumab, MEDI4736 alone, or tremelimumab alone in gastric or gastroesophageal …

• CLINICAL_TRIALS trial_result · 2020-05-07
  Clinical Trial Update: A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers [Phase 1]

  A Phase 1 pilot study evaluating the safety and feasibility of adding FOLFIRINOX chemotherapy to neoadjuvant radiation for gastric and gastr…

• FDA label_change · 2020-03-19
  FDA Approved: ONTRUZANT — Supplemental Application (Organon LLC)

  FDA approves a supplemental application for ONTRUZANT (trastuzumab) filed by Organon LLC, resulting in changes to the product labeling.

• CLINICAL_TRIALS trial_result · 2020-02-10
  Clinical Trial Update: The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma. [Phase 2]

  A Phase 2 clinical trial evaluating sintilimab in combination with Xelox as neoadjuvant therapy for resectable locally advanced gastric or g…

• CLINICAL_TRIALS trial_result · 2020-02-10
  Clinical Trial Update: Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) [Phase 2]

  Phase 2 trial evaluating preoperative chemotherapy and chemoradiotherapy for adenocarcinoma of the stomach and gastroesophageal junction has…

• CLINICAL_TRIALS trial_result · 2020-01-07
  Clinical Trial Update: Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer [Phase 2]

  Phase II study of ramucirumab in combination with chemotherapy for metastatic gastric/gastroesophageal junction cancer was terminated; resul…

• CLINICAL_TRIALS trial_result · 2019-10-09
  Clinical Trial Update: A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 trial evaluating oxaliplatin, capecitabine, and trastuzumab with chemoradiotherapy as adjuvant therapy in operable HER2-positive gas…

• CLINICAL_TRIALS trial_result · 2019-09-18
  Clinical Trial Update: Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma [Phase 2]

  Phase 2 trial evaluating capecitabine, carboplatin, and bevacizumab for gastroesophageal junction and gastric cancer has completed, with res…

• CLINICAL_TRIALS trial_result · 2019-09-11
  Clinical Trial Update: FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer [Phase 2]

  A phase 2 trial evaluating FDG-PET directed treatment for locally advanced gastric and gastroesophageal junction adenocarcinoma was terminat…

• CLINICAL_TRIALS trial_result · 2019-09-04
  Clinical Trial Update: Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer [Phase 2]

  Phase 2 trial assessing a chemotherapy combination (cisplatin-fluorouracil-afatinib) in patients with inoperable gastric or gastroesophageal…

• CLINICAL_TRIALS trial_result · 2019-08-21
  Clinical Trial Update: A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer [Phase 1, Phase 2]

  Phase 1/2 study updates on ramucirumab plus nivolumab in gastric and GEJ cancer completed.

• CLINICAL_TRIALS trial_result · 2019-08-20
  Clinical Trial Update: Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ [Phase 1, Phase 2]

  Phase 1/2 clinical trial evaluating toripalimab with preoperative chemoradiotherapy for locally advanced esophagogastric junction cancer.

• CLINICAL_TRIALS trial_result · 2019-08-12
  Clinical Trial Update: A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer [Phase 1, Phase 2]

  A clinical trial evaluating gentuximab plus paclitaxel in advanced gastric or gastroesophageal junction cancer is in Phase 1/2 with status c…

• CLINICAL_TRIALS trial_result · 2019-05-16
  Clinical Trial Update: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 clinical trial evaluating oxaliplatin, capecitabine (Xeloda), and cetuximab as first-line therapy for metastatic or unresectable gas…

• FDA approval · 2019-04-17
  FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)

  The FDA approved Biocon Biologics' supplemental application for OGIVRI (trastuzumab-dkst), a trastuzumab biosimilar.